Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma
Also known as: HIV QNT
Use
This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of HIV-1 infected patients. It can assess patient prognosis by measuring baseline HIV-1 levels and monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels during treatment.
Special Instructions
Separate plasma from cells within 24 hours of collection. Transfer 2 mL plasma to an ARUP standard transport tube. Ensure the specimen is shipped frozen to preserve stability.
Limitations
The quantitative range of this assay is 1.30-7.00 log copies/mL (20-10,000,000 copies/mL). A result of 'Not Detected' does not rule out the presence of inhibitors or HIV-1 RNA concentration below the detection level of the test. This assay should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- or tissue-based products (HCT/P).
FDA ApprovedNew York Approved
Methodology
PCR-based (qPCR)
Biomarkers
LOINC Codes
- 20447-9
- 29541-0
- 25835-0
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1.3 mL
Container
ARUP standard transport tube
Collection Instructions
Separate plasma from cells within 24 hours of collection.
Storage Instructions
Ship frozen.
Causes for Rejection
Serum. CSF. Heparinized specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 6 days |
| Frozen | 3 months |